Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion type Assertion NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_head.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion description "[A subset of the cancer cell lines with a range of responses to TRAIL was selected from the panel for treatment with TRAIL combined with the PI3 Kinase/mTOR inhibitor PI-103 or the HSP90 inhibitor 17-AAG (tanespimycin).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion evidence source_evidence_literature NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion SIO_000772 23852390 NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion wasDerivedFrom befree-20150227 NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.
- NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_assertion wasGeneratedBy ECO_0000203 NP804321.RAmcGsXdNRar0RPk5UIeWOHOu8H8aHcQY395xwkbvvvgY130_provenance.